"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial looking at chemotherapy for Burkitt's or Burkitt's like non Hodgkin lymphoma (LY10)
This trial was trying to find out more about Burkitt’s lymphoma and to see if it was safe to treat this type of lymphoma with a reduced dose of chemotherapy. This trial was supported by Cancer Research UK.
Burkitt’s lymphoma is a rare form of non Hodgkin lymphoma (NHL). It is a type of high grade B cell lymphoma that occurs mostly in young adults.
Doctors use a combination of chemotherapy drugs to treat Burkitt’s lymphoma. This works very well, but it is quite intensive treatment and does have side effects. In this trial, they wanted to see if a slightly lower dose of drugs works just as well, but has fewer side effects.
An extra part of this study involved sending a tissue sample (
The aims of the trial were to learn more about Burkitt’s lymphoma. And to see if a reduced dose of chemotherapy
- Worked as well as the standard treatment
- Had fewer side effects
Summary of results
The researchers compared their results with earlier trials, and found that a lower dose of chemotherapy worked about as well, and had fewer side effects.
The trial recruited 128 people and 110 went on to have chemotherapy. Depending on the stage of their disease and how fit they were, the researchers classed them as being either high risk or low risk for their lymphoma coming back.
People classed as low risk had a combination of drugs called CODOX-M. People in the high risk group had a combination containing some extra drugs called CODOX-M/IVAC. Everybody had a reduced dose of one of the drugs called methotrexate. The trial team reported that this reduced the number of side effects, such as fewer people getting a sore mouth.
The new, specialist tests that were carried out on the tumour samples involved looking closely at the genetic material (the DNA). This type of testing is called
The researchers found that compared to older types of testing, cytogenetics, was a better way of seeing the difference between Burkitt’s lymphoma and another type of high grade lymphoma called diffuse large B cell lymphoma (DLBCL).
Together with this information, they looked at the number of people who had no signs of their cancer coming back 2 years after treatment. This was
- 26 out of 42 people (62%) who had high risk Burkitt’s lymphoma
- 8 out of 11 people (73%) who had low risk Burkitt’s lymphoma
- 12 out of 35 people (34%) who had high risk DLBCL
- 19 out of 22 people (86%) who had low risk DLBCL
The trial team suggest that this lower dose of chemotherapy can be used safely for people who have Burkitt’s lymphoma. But people who have other types of high grade B cell lymphoma should have different treatment.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr G Mead
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Medical Research Council (MRC)
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUK/01/006.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040